Regulatory Strategy
Regulatory Strategy for Critical FDA Milestones
FDA Connection Group Inc. offers regulatory strategy backed by our years of experience. We help clinical-stage companies navigate pre-IND planning, FDA meetings, development strategy, and submission pathways with confidence.
Milestone Planning
Strategic planning for key FDA interactions and submissions.
FDA Meeting Strategy
Expert guidance for productive and impactful FDA meetings.
Program Risk Reduction
Proactive strategies to identify and mitigate risks.
How We Support
How We Support Regulatory Strategy
We provide strategic regulatory guidance tailored to your program’s stage, goals, and therapeutic area, combining experienced FDA regulatory strategy and submission support. with practical, real-world experience.
Pre-IND and Early Development Strategy
Define regulatory strategy, program design, and data requirements for a strong start and efficient development.
FDA Meeting Planning and Briefing Packages
Develop comprehensive briefing packages and strategic approaches for Type B, Type C, and other key FDA meetings.
IND to BLA Regulatory Roadmapping
Create end-to-end regulatory roadmaps aligned with your development timeline, product goals, and FDA expectations.
Breakthrough/Orphan/Expedited Program Support
Assess eligibility and prepare requests for applicable expedited programs and designations.
Support Across Key FDA Interactions
We help you prepare for and maximize the success of every critical FDA interaction throughout your product’s lifecycle.
Pre-IND
Strategy, data requirements, and initial regulatory feedback.
Type B Meetings
Align on development plans and critical path decisions.
Type C Meetings
Address specific questions and obtain targeted feedback.
End of Phase 2
Seek FDA feedback on proposed Phase 3 design and registration strategy.
Phase 3 Readiness
Assess alignment and identify gaps across clinical, CMC, and regulatory requirements.
BLA Readiness
Finalize submission strategy and prepare for filing.
What Strategic Support Includes
Our comprehensive regulatory strategy services help you make informed decisions, reduce risk, and keep your program on track.
Regulatory Gap Assessment
Evaluate your current program against FDA requirements and identify key gaps and opportunities.
Development Pathway Analysis
Assess regulatory pathways, development options, and key decision points.
Submission Sequencing Strategy
Optimize timing and sequencing of INDs, amendments, and future submissions.
FDA Question Response Support
Prepare strategic, clear, and compelling responses to FDA questions and information requests.
Cross-Functional Program Alignment
Work with your internal teams to align regulatory, clinical, CMC, and commercial goals.
Why Sponsors Choose FCG
We combine deep regulatory expertise, real-world experience, and a collaborative, hands-on approach to help clinical-stage companies achieve their development goals.
Deep Regulatory Expertise
Decades of experience with FDA submissions and regulatory strategy.
Practical, Real-World Recommendations
Actionable guidance based on real-world experience, not just theoretical approaches.
Integrated Strategy + Operations
Seamless alignment between regulatory strategy, submissions, and program execution.
Hands-On Client Partnership
We work as an extension of your team, providing personalized, responsive support.
Let's Work Together
Let's Build Your Regulatory Strategy
Whether you are preparing for a pre-IND meeting, planning your development program, or approaching a key FDA milestone, our team is here to help. Discuss your goals and how we can support your program’s success.
FDA Regulatory Strategy — From IND Development Through BLA Readiness
Expert-led regulatory planning, FDA meeting preparation, and submission strategy for clinical-stage pharmaceutical and biotechnology companies.
FDA Connection Group, Inc. (FCG) combines regulatory expertise, structured program management, and hands-on submission experience to help sponsors navigate complex FDA development milestones.
We work alongside clinical, statistical, CMC, and management teams to identify regulatory risks, prepare FDA interactions, and translate development objectives into coordinated regulatory action plans.
FDA Meetings and Briefing Packages
FCG provides regulatory strategy and document development services for important FDA interactions, including:
- Pre-IND meetings and early development consultations.
- Type B, Type C, and Type D meeting requests.
- End-of-Phase 2 meeting requests and briefing packages.
- Clinical efficacy and safety data integration.
- Development of proposed FDA questions and sponsor positions.
- Phase 3 readiness and regulatory gap assessments.
- Meeting package preparation, regulatory QC, and eCTD submission support.
IND-to-BLA Development Strategy
Our services support sponsors in evaluating clinical evidence, manufacturing readiness, regulatory dependencies, and submission requirements throughout the development lifecycle.
We help identify outstanding issues, establish regulatory priorities, and develop practical plans for upcoming FDA milestones.
Integrated Regulatory Intelligence
FCG Regulatory AI, powered by FCG-OS™
Our evolving program intelligence framework is designed to combine structured regulatory information, controlled workflows, and supervised AI with experienced human regulatory oversight.
The objective is greater visibility into program milestones, outstanding regulatory issues, documentation readiness, and critical development decisions.
Discuss Your Regulatory Program
Whether your company is preparing an FDA meeting, submitting an IND amendment, or planning its next clinical development milestone, FCG can help assess your regulatory needs and define an appropriate scope of support.
Contact FDA Connection Group to discuss your development program.
The FCG-OS™ language deliberately describes an evolving framework rather than implying that every AI capability is already deployed and commercially validated.